Skip to content
Screener

Common Stock at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$236K+2.6%
ALN
Alnylam PharmaceuticalsALNY
250M0.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.44B+2.0%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
300M0.0%
Absci Corporation logo
Absci CorporationABSI
$17K+30.8%

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$528.72M+193%
Enterprise value$500.1M+213%
P/S7.4×+2.0×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211987
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 15,892,353 and 15,855,329 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1616
Additional paid-in capital1,040,0881,038,823
Accumulated other comprehensive loss(368)(41)
Accumulated deficit(841,126)(832,047)
Total stockholders' equity198,610206,751

Item 1. Financial Statements

FAQ

What is Assembly Biosciences's common stock?
Assembly Biosciences (ASMB) reported common stock of $16K in Q1 2026.
How has Assembly Biosciences's common stock changed year-over-year?
Assembly Biosciences's common stock increased by 100.0% year-over-year, from $8K to $16K.
What is the long-term trend for Assembly Biosciences's common stock?
Over 5 years (2020 to 2025), Assembly Biosciences's common stock has grown at a -14.0% compound annual growth rate (CAGR), from $34K to $16K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Assembly Biosciences's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude